Literature DB >> 964292

Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. II. Relationship to its effect on blood pressure and plasma renin activity.

P Collste, K Haglund, M Frisk-Holmberg, M L Orme, M D Rawlins, J Ostman.   

Abstract

The kinetics of alprenolol, in relation to its effect on blood pressure and plasma renin activity, have been studied in sixteen patients. A within-patient comparison was made between therapy for six weeks with placebo or alpronolol 200 mg thrice daily. Thirteen patients responded to alprenolol by a signoficant fall in blood pressure. In three other patients treatment did not lower blood pressure. In the group as a whole there was no significant correlation between the fall in systolic, diastolic or mean blood pressure, and the steady-state plasma alprenolol concentration, renin status, or degree of beta blockade. However, the thirteen responsive patients showed a significant relationship (p less than 0.05 - 0.001) between the log mean steady-state plasma alprenolol concentration and the hypotensive response.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 964292     DOI: 10.1007/BF00609465

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. I. Relationship between plasma concentration and adrenergic beta-receptor blockade.

Authors:  P Collste; K Haglund; M Frisk-Holmberg; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

2.  Comparison between alprenolol and propranolol as antihypertensive agents. A double-blind cross-over study.

Authors:  C Bengtsson
Journal:  Acta Med Scand       Date:  1972-11

3.  Adrenergic receptor mediation of renin secretion.

Authors:  N Winer; D S Chokshi; M S Yoon; A D Freedman
Journal:  J Clin Endocrinol Metab       Date:  1969-09       Impact factor: 5.958

4.  Controlled trial of oxprenolol and practolol in hypertension.

Authors:  A W Leishman; J L Thirkettle; B R Allen; R A Dixon
Journal:  Br Med J       Date:  1970-11-07

5.  Antihypertensive therapy with alprenolol, a beta-adrenergic receptor antagonist.

Authors:  G Tibblin; B Ablad
Journal:  Acta Med Scand       Date:  1969-11

6.  Steady-state plasma concentrations of alprenolol in man.

Authors:  M D Rawlins; P Collste; M Frisk-Holmberg; M Lind; J Ostman; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

7.  Essential hypertension: renin and aldosterone, heart attack and stroke.

Authors:  H R Brunner; J H Laragh; L Baer; M A Newton; F T Goodwin; L R Krakoff; R H Bard; F R Bühler
Journal:  N Engl J Med       Date:  1972-03-02       Impact factor: 91.245

8.  Central hypotensive activity of dl- and d-propranolol.

Authors:  G J Kelliher; J P Buckley
Journal:  J Pharm Sci       Date:  1970-09       Impact factor: 3.534

9.  Evaluation of the hypotensive effect of beta-adrenergic blockade in hypertension.

Authors:  S Dorph; C Binder
Journal:  Acta Med Scand       Date:  1969-05

10.  Potency and time-effect relationship in man of propranolol and H 56-28--comparative studies after oral administration.

Authors:  B Ablad; G Johnsson; A Norrby; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1967
View more
  14 in total

1.  Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. I. Relationship between plasma concentration and adrenergic beta-receptor blockade.

Authors:  P Collste; K Haglund; M Frisk-Holmberg; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

Review 2.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

3.  Antihypertensive action of beta-adrenoceptor blockade and the renin-angiotensin system.

Authors:  I Gavras; H Gavras; H R Brunner; C S Liang
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

4.  Acebutolol in hypertension: relationships between drug concentration and effects.

Authors:  M A Martin; F C Phillips; G T Tucker; A J Smith
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

5.  Relationship between the antihypertensive effect and steady-state plasma concentration of nifedipine given alone or in combination with a beta-adrenoceptor blocking agent.

Authors:  O Lederballe Pedersen; C K Christensen; E Mikkelsen; K D Rämsch
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

6.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

Review 7.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

8.  Monoamine metabolites in cerebrospinal fluid during treatment with clonidine or alprenolol.

Authors:  L Bertilsson; K Haglund; J Ostman; M D Rawlins; V A Ringberger; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1977-01-03       Impact factor: 2.953

9.  Pharmacokinetics of tolamolol in the treatment of hypertension.

Authors:  P A Routledge; D M Davies; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1977-11-14       Impact factor: 2.953

10.  Antihypertensive effect of various doses of hydrochlorothiazide and its relation to the plasma level of the drug.

Authors:  B Beermann; M Groschinsky-grind
Journal:  Eur J Clin Pharmacol       Date:  1978-05-31       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.